CSIMarket
 


Pulmatrix Inc   (PULM)
Other Ticker:  
 

Pulmatrix Inc 's Quick Ratio

PULM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 4.82 below Pulmatrix Inc average.

Within Major Pharmaceutical Preparations industry 197 other companies have achieved higher Quick Ratio than Pulmatrix Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 590, from total ranking in the second quarter 2023 at 676.

Explain Quick Ratio?
How much Cash & cash equivalents PULMīs has?
What are PULMīs Current Liabilities?


PULM Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -12.18 % -16.93 % -26.48 % -6.24 % 19.11 %
Y / Y Cash & cash equivalent Change -47.75 % -40.1 % -35.3 % -33.54 % -23.66 %
Quick Ratio MRQ 4.82 7.96 7.78 8.59 8.1
PULM's Total Ranking # 590 # 676 # 509 # 479 # 523
Seq. Current Liabilities Change 36.74 % -18.06 % -5.09 % -17.41 % 29.34 %
Seq. Cash & cash equivalent Change -17.27 % -16.14 % -14.05 % -12.38 % -5.16 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 198
Healthcare Sector # 330
Overall Market # 590


Quick Ratio Statistics
High Average Low
19.22 5.03 0.25
(Jun 30 2015)   (Mar 31 2018)




Financial Statements
Pulmatrix Inc 's Current Liabilities $ 4 Millions Visit PULM's Balance sheet
Pulmatrix Inc 's Cash & cash equivalent $ 21 Millions Visit PULM's Balance sheet
Source of PULM's Sales Visit PULM's Sales by Geography


Cumulative Pulmatrix Inc 's Quick Ratio

PULM's Quick Ratio for the trailling 12 Months

PULM Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -12.18 % -16.93 % -26.48 % -6.24 % 19.11 %
Y / Y Cash & cash equivalent TTM Growth -47.75 % -40.1 % -35.3 % -33.54 % -23.66 %
Quick Ratio TTM 7.2 8.12 8.82 9.05 9.88
Total Ranking TTM # 3310 # 4993 # 4256 # 4096 # 389
Seq. Current Liabilities TTM Growth 36.74 % -18.06 % -5.09 % -17.41 % 29.34 %
Seq. Cash & cash equivalent TTM Growth -17.27 % -16.14 % -14.05 % -12.38 % -5.16 %


On the trailing twelve months basis In spite of the year on year decrease in PULM's Current Liabilities to $4.43 millions, cumulative Quick Ratio to 7.2 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 471 other companies have achieved higher Quick Ratio than Pulmatrix Inc . While Quick Ratio overall ranking has improved so far to 3310, from total ranking during the twelve months ending second quarter 2023 at 4993.

Explain Quick Ratio?
How much Cash & cash equivalents PULMīs has?
What are PULMīs Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 472
Healthcare Sector # 958
Within the Market # 3310


trailing twelve months Quick Ratio Statistics
High Average Low
9.69 3.93 0.89
(Mar 31 2022)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Kezar Life Sciences Inc   13.09 $ 218.205  Millions$ 16.672  Millions
Rocket Pharmaceuticals Inc   13.06 $ 437.171  Millions$ 33.476  Millions
Briacell Therapeutics Corp   13.04 $ 13.646  Millions$ 1.047  Millions
Vistagen Therapeutics Inc   12.93 $ 37.608  Millions$ 2.910  Millions
Rallybio Corporation  12.91 $ 121.384  Millions$ 9.402  Millions
Io Biotech Inc   12.75 $ 165.501  Millions$ 12.985  Millions
Relmada Therapeutics Inc   12.62 $ 106.267  Millions$ 8.422  Millions
Prothena Corporation Public Limited Company  12.57 $ 670.897  Millions$ 53.370  Millions
Biomea Fusion Inc   12.28 $ 199.090  Millions$ 16.210  Millions
Ligand Pharmaceuticals Incorporated  12.11 $ 190.502  Millions$ 15.727  Millions
Oric Pharmaceuticals Inc   12.00 $ 227.296  Millions$ 18.944  Millions
Anebulo Pharmaceuticals Inc   11.89 $ 8.521  Millions$ 0.717  Millions
Ovid Therapeutics Inc   11.70 $ 87.072  Millions$ 7.439  Millions
Gh Research Plc  11.70 $ 78.420  Millions$ 6.701  Millions
Sensei Biotherapeutics Inc   11.57 $ 72.013  Millions$ 6.226  Millions
Protagonist Therapeutics inc   11.51 $ 320.751  Millions$ 27.867  Millions
Ventyx Biosciences Inc   11.48 $ 300.819  Millions$ 26.208  Millions
Cormedix Inc   11.29 $ 86.587  Millions$ 7.671  Millions
Artelo Biosciences Inc   11.10 $ 10.225  Millions$ 0.921  Millions
Erasca Inc   11.10 $ 296.668  Millions$ 26.730  Millions
Anaptysbio Inc   11.03 $ 413.047  Millions$ 37.437  Millions
Mei Pharma Inc   10.95 $ 82.202  Millions$ 7.509  Millions
Ocuphire Pharma Inc   10.84 $ 42.361  Millions$ 3.909  Millions
Atai Life Sciences N v   10.77 $ 208.994  Millions$ 19.403  Millions
Nkarta Inc   10.75 $ 275.613  Millions$ 25.640  Millions
Lipocine Inc   10.64 $ 23.848  Millions$ 2.241  Millions
Kinnate Biopharma Inc   10.62 $ 167.576  Millions$ 15.774  Millions
Caladrius Biosciences Inc   10.60 $ 54.394  Millions$ 5.132  Millions
Pasithea Therapeutics Corp   10.53 $ 19.680  Millions$ 1.869  Millions
Cryoport inc   10.41 $ 467.518  Millions$ 44.905  Millions

Date modified: 2024-02-17T23:51:24+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com